KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Operating Income (2016 - 2025)

Pfizer (PFE) has disclosed Operating Income for 17 consecutive years, with $4.0 billion as the latest value for Q4 2025.

  • Quarterly Operating Income changed N/A to $4.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $20.7 billion for FY2025, 156.03% up from the prior year.
  • Operating Income for Q4 2025 was $4.0 billion at Pfizer, up from -$7.8 billion in the prior quarter.
  • The five-year high for Operating Income was $13.0 billion in Q3 2022, with the low at -$13.3 billion in Q4 2023.
  • Average Operating Income over 5 years is $1.7 billion, with a median of $5.0 billion recorded in 2025.
  • Peak annual rise in Operating Income hit 175.23% in 2024, while the deepest fall reached 470.18% in 2024.
  • Over 5 years, Operating Income stood at $7.9 billion in 2021, then soared by 30.57% to $10.3 billion in 2022, then plummeted by 229.48% to -$13.3 billion in 2023, then increased by 17.61% to -$11.0 billion in 2024, then soared by 136.83% to $4.0 billion in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at $4.0 billion, -$7.8 billion, and $5.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.